Collaborations & Alliances

Gilead, Nurix Therapeutics Extend Strategic Research Pact

Nurix will receive a $15 million extension fee and remains eligible for up to $73.5 million in preclinical milestones and potential future licensing payments.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company developing targeted protein modulation drugs to treat cancer and inflammatory diseases, announced that Gilead Sciences has extended the research term of the companies’ ongoing collaboration by an additional two years.   Under the collaboration, Nurix is deploying its drug discovery platform to identify novel agents that use E3 ligases to induce degradation of specified drug targets. Gilead has an option to license resulting d...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters